Case-Based Conversations on Neuromodulation, Inflammation, Eyelid Margin Disease, and ADC-Related Ocular Toxicity

Activity Description

This course brings together four expert optometrists to explore the diagnosis and management of ocular surface disease, including Demodex blepharitis, meibomian gland dysfunction, dry eye disease, and inflammation, while also addressing the recognition and management of antibody-drug conjugate related ocular toxicities in oncology patients.

Accreditation Statements

Sponsored by

NSUOCO

Axiom Ophthalmic, LLC is a COPE-Approved Administrator.

This activity, COPE Activity Number 133116, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hours of CE.

Course # 104785-TD
Activity # 133116

COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

Release Date: 7-31-2026
Expiration Date: 07-31-2027

Target Audience

This accredited educational activity is designed for optometrists.

Grant Support Statement

This activity is supported by an unrestricted educational grant from AbbVie, Harrow, Sight Sciences, Sun Pharma, and Tarsus.

Faculty

Marc Bloomenstein, OD, FAAO

Program Chair
Schwartz Laser Eye Center
Phoenix, Arizona

Mile Brujic, OD, FAAO

Premier Vision Group
Bowling Green, Ohio

Cecelia Koetting, OD, FAAO, DipABO

Assistant Professor, Ophthalmology
University of Colorado School of Medicine
Aurora, Colorado

Jacob Lang, OD, FAAO

Associated Eye Care
Stillwater, Minnesota

Program Description

Faculty

Marc Bloomenstein, OD, FAAO
Mile Brujic, OD, FAAO
Cecelia Koetting, OD, FAAO, DipABO
Jacob Lang, OD, FAAO

Learning Objectives

After completing this course, learners will be able to:

Identify and stage patients with eyelid margin disease (meibomian gland dysfunction [MGD] and Demodex Blepharitis [DB]), tear deficiency, and acute and chronic ocular Inflammation by incorporating consistent examination techniques to recognize the pathognomonic signs.
Assess traditional and emerging diagnostic methods, including tear osmolarity, MMP-9, anterior segment OCT, meibography/gland expression, collarette detection, and incorporate validated symptom questionnaires and objective clinical data to improve the accuracy of OSD/DED diagnosis.
Evaluate the various treatment options and apply evidence-based selection criteria to customize management strategies for the latest DB pharmaceuticals, neuromodulation therapies, anti-inflammatories (acute and chronic), mechanical and pharmacological MGD treatments.
Recognize the ocular findings associated with antibody-drug conjugates (ADCs) for the treatment of certain cancers, perform the appropriate baseline and follow-up ophthalmic exams for patients receiving ADC therapy, and develop effective communication strategies with the patient’s shared care team.

Credit

This enduring educational activity is eligible for 0.5 hours of COPE credit.

1 - Introduction - Case-Based Conversations on Neuromodulation, Inflammation, Eyelid Margin Disease, and ADC-Related Ocular Toxicity
2 - Activity - Case-Based Conversations on Neuromodulation, Inflammation, Eyelid Margin Disease, and ADC-Related Ocular Toxicity
3 - Evaluation - Case-Based Conversations on Neuromodulation, Inflammation, Eyelid Margin Disease, and ADC-Related Ocular Toxicity

Progress